---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-027887"
form_type: "8-K"
ticker: "INM"
cik: "0001728328"
company_name: "InMed Pharmaceuticals Inc."
filed_at: "2022-05-18T23:59:59+00:00"
generated_at: "2026-06-25T10:04:58.072233+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# InMed Q3 FY2022 net loss $10.7M; revenue $0.6M from BayMedica; board adds Baldasare

## Summary
- Net loss for 9 months ended Mar 31, 2022: $10.7M ($0.81/share) vs $6.9M ($1.11/share) prior year.
- BayMedica generated $0.6M revenue from rare cannabinoid sales; gross profit $0.3M.
- Cash, cash equivalents and short-term investments $5.9M vs $7.4M at June 30, 2021.
- Appointed Bryan Baldasare to Board of Directors; board expanded to six members.
- Phase 2 trial of INM-755 for EB continues; pIND for INM-088 glaucoma aligns with FDA.

## SEC filing metadata
- accession: 0001213900-22-027887
- form_type: 8-K
- ticker: INM
- cik: 0001728328
- company_name: InMed Pharmaceuticals Inc.
- filed_at: 2022-05-18T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1728328/000121390022027887/0001213900-22-027887-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1728328/000121390022027887/ea160171-8k_inmedphar.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-027887
- JSON: https://secwatch.observer/filing/0001213900-22-027887.json
- Plain text: https://secwatch.observer/filing/0001213900-22-027887.txt

## Key facts
- Executive change
  Bryan Baldasare was appointed as director at InMed Pharmaceuticals Inc..
  - Action: appointed
  - Role: director
  source text: On May 12, 2022, the Board appointed Bryan Baldasare as a director of the Board and concurrently increased the size of the Board to six members, effective as of May 12, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1728328/000121390022027887/0001213900-22-027887-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.